Abstract:We recently identified thrombospondin-2 (TSP-2) as an endogenous regulator of matrix remodelling and inflammation in experimental kidney disease by studying TSP-2-deficient mice. In this study, we asked whether systemic TSP-2 overexpression via thigh muscle transfection is able to ameliorate the time course of the anti-Thy1 glomerulonephritis model. After induction of anti-Thy1 nephritis, rats were transfected either with an overexpression plasmid for TSP-2 or lacZ as a control. Biopsies, urine, and blood samp… Show more
“…In accordance to our previous short term (one week) study in an acute glomerulonephritis model [15], we now demonstrate that the apparent competition of long-term TSP-2 therapy with endogenously increased TSP-1 was able to specifically inhibit TGF-β activation in CAN as assessed at the end point 7 months after application. Furthermore, we could demonstrate marked anti-inflammatory properties during CAN decreasing renal accumulation of T-cells, B-cells and macrophages by long-term TSP-2 gene therapy.…”
Section: Discussionsupporting
confidence: 91%
“…In healthy rat kidneys, TSP-1 as well as TSP-2 staining was absent within the glomeruli and rarely found within the tubulointerstitial compartment (data not shown, see [15]). In contrast, thirty weeks after kidney transplantation remarkable TSP-1 staining could be detected within the Bowman's capsule and to a lesser extent in the glomerular tuft of glomeruli with pronounced pathological changes (Fig.…”
Section: Resultsmentioning
confidence: 87%
“…Briefly, mTSP-2 was cut from pcDNA3.1 (kindly provided by M. Streit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA) using Eco RI and XbaI and subsequently ligated into pUbMCS digested equally. Transfection of left and right thigh muscles with 35 µg plasmid DNA containing mouse TSP-2 or luciferase DNA (control) was performed as descibed previously [15]. For evaluation of long-term expression, the ubiquitin-driven luciferase plasmid was compared with the commercially available pGl2 vector using the transfection conditions as mentioned above.…”
Section: Methodsmentioning
confidence: 99%
“…In a recent study in an acute glomerulonephritis model in the rat we used TSP-2 gene therapy in the thigh muscle to competitively block TSP-1 mediated TGF-β activation. Hereby, TSP-2 overexpression resulted in significant reduction of TGF-β activation and subsequent matrix accumulation and inhibited the glomerular proliferative and inflammatory response [15]. In addition, hearts of TSP-2 deficient mice show either age-related or after viral infection an increased fibrotic and inflammatory response [16], [17].…”
We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature.
“…In accordance to our previous short term (one week) study in an acute glomerulonephritis model [15], we now demonstrate that the apparent competition of long-term TSP-2 therapy with endogenously increased TSP-1 was able to specifically inhibit TGF-β activation in CAN as assessed at the end point 7 months after application. Furthermore, we could demonstrate marked anti-inflammatory properties during CAN decreasing renal accumulation of T-cells, B-cells and macrophages by long-term TSP-2 gene therapy.…”
Section: Discussionsupporting
confidence: 91%
“…In healthy rat kidneys, TSP-1 as well as TSP-2 staining was absent within the glomeruli and rarely found within the tubulointerstitial compartment (data not shown, see [15]). In contrast, thirty weeks after kidney transplantation remarkable TSP-1 staining could be detected within the Bowman's capsule and to a lesser extent in the glomerular tuft of glomeruli with pronounced pathological changes (Fig.…”
Section: Resultsmentioning
confidence: 87%
“…Briefly, mTSP-2 was cut from pcDNA3.1 (kindly provided by M. Streit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA) using Eco RI and XbaI and subsequently ligated into pUbMCS digested equally. Transfection of left and right thigh muscles with 35 µg plasmid DNA containing mouse TSP-2 or luciferase DNA (control) was performed as descibed previously [15]. For evaluation of long-term expression, the ubiquitin-driven luciferase plasmid was compared with the commercially available pGl2 vector using the transfection conditions as mentioned above.…”
Section: Methodsmentioning
confidence: 99%
“…In a recent study in an acute glomerulonephritis model in the rat we used TSP-2 gene therapy in the thigh muscle to competitively block TSP-1 mediated TGF-β activation. Hereby, TSP-2 overexpression resulted in significant reduction of TGF-β activation and subsequent matrix accumulation and inhibited the glomerular proliferative and inflammatory response [15]. In addition, hearts of TSP-2 deficient mice show either age-related or after viral infection an increased fibrotic and inflammatory response [16], [17].…”
We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature.
“…Harvested kidneys were fixed in Zn fixative overnight and were further processed as previously described (12). Paraffin-embedded kidneys were cut into 2-m-thick sections.…”
. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307: F317-F325, 2014. First published June 18, 2014 doi:10.1152/ajprenal.00145.2014.-Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na ϩ -glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-LepϽobϾ/WiscJ (BTBR ob/ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ob mice received 1 g·kg body wt Ϫ1 ·day
Ϫ1ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetesrelated glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ob mice with and without hypertension.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.